Clinical trial NCT01335269: A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer
Official title: An Open Label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Patients With Various Advanced or Metastatic Non-hematologic Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Neoplasms
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2011-04-14
Enrollment: 96
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of this trial is to determine the safety and tolerability of BI 853520 monotherapy by defining the maximum tolerated dose (MTD) and recommending the dose for further trials in the development of this compound.

Secondary objectives are

* determination of the pharmacokinetic (PK) profile;
* exploratory pharmacodynamic analysis; and
* collection of preliminary data on anti-tumour efficacy.


Eligibility criteria: Inclusion criteria:

Inclusion criteria

1. Patients with a confirmed diagnosis of advanced, measurable or evaluable, nonresectable and/or metastatic non-hematologic malignancy, which has shown to be progressive in the last 6 months as demonstrated by serial imaging
2. Patients who have failed conventional treatment or for whom no therapy of proven efficacy exists or who are not amenable to established treatment options
3. Tumour tissue must be available for the determination of E-cadherin expression (archived tissue or fresh biopsy).
4. Recovery from reversible toxicities (alopecia excluded) of prior anti-cancer therapies (CTCAE grade \< 2)
5. Age = 18 years
6. Life expectancy = 3 months
7. Written informed consent in accordance with International Conference on Harmonisation/Good Clinical Practice (ICH/GCP) and local legislation, including consent for PK samples, for using an archived tumour sample for determination of Ecadherin status, for reviewing previous tumour scans (and for providing skin biopsies, in patients in dose finding phase enrolled before protocol amendment 03)
8. Eastern Cooperative Oncology Group (ECOG), R01-0787) performance score 0-1

   Additional inclusion criteria in the expansion phase:
9. Patients must have measurable progressive disease within the last 6 months, according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (version 1.1, R09-0262)
10. deleted
11. Patients must be willing to provide paired tumour biopsies for PD determination. Refer to section 5.6.3
12. Patients should fit into one of the categories described below:

I. Metastatic adenocarcinoma of the pancreas Patients should have preferably received at least one line of systemic treatment for metastatic disease and preferably not more than 2 prior regimens for metastatic disease.

II. Platinum-resistant ovarian carcinoma, defined as recurrence within 6 months after completion of prior platinum-based chemotherapy Patients should have received preferably no more than 5 previous lines of systemic treatment for metastatic disease.

III. Oesophageal carcinoma Patients with oesophageal carcinoma of adenocarcinoma- or squamous cell histology who have received preferably not more than 2 previous lines of systemic treatment for metastatic disease.

IV. Soft tissue sarcoma Patients should preferably have received no more than 2 previous lines of systemic treatment for metastatic disease.

Exclusion criteria:

* Serious concomitant non-oncological disease/illness
* Active/symptomatic brain metastases
* Second malignancy
* Pregnancy or breastfeeding
* Women or men who are sexually active and unwilling to use a medically acceptable method of contraception.
* Treatment with cytotoxic anti-cancer-therapies or investigational drugs within four weeks of the first treatment with the study medication

Primary outcomes:
measure: Determination of the MTD. It will be defined by the occurrence of dose-limiting toxicities (DLT) during the first treatment cycle of each patient in the dose finding phase
timeFrame: After the first 28 days of treatment
Secondary outcomes:
measure: Cmax (maximum measured concentration of the analyte in plasma) after first dose
timeFrame: up to 48 hours
measure: AUCt,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval t after administration of the first dose)
timeFrame: up to 48 hours
measure: Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t) after the last dose in cycle 1
timeFrame: up to 24 hours
measure: AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t) after the last dose in cycle 1
timeFrame: up to 24 hours
measure: Disease control rate (CR or PR or SD per RECIST v1.1) )
timeFrame: up to 39 months
measure: Duration of disease control (measured from drug start date to the date of disease progression for patients who had CR or PR or SD during treatment)
timeFrame: up to 39 months
measure: Objective response rate (CR or PR per RECIST v1.1)
timeFrame: up to 39 months
measure: Tumour shrinkage (in millimetre) defined as change from baseline to the minimum post-baseline sum of diameters of target lesions.
timeFrame: up to 39 months
measure: Pharmacodynamic assessment: phosphorylated and total PTK2 (FAK) modulation in tumour biopsies
timeFrame: baseline, day 22 and day 28
Other outcomes:
Locations:
city: Hamilton
country: Canada
facility: 1300.2.1002 Boehringer Ingelheim Investigational Site
state: Ontario
city: Toronto
country: Canada
facility: 1300.2.1001 Boehringer Ingelheim Investigational Site
state: Ontario
city: Amsterdam
country: Netherlands
facility: 1300.2.31003 Boehringer Ingelheim Investigational Site
city: Rotterdam
country: Netherlands
facility: 1300.2.31001 Boehringer Ingelheim Investigational Site
city: Utrecht
country: Netherlands
facility: 1300.2.31002 Boehringer Ingelheim Investigational Site
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References:
citation: de Jonge MJA, Steeghs N, Lolkema MP, Hotte SJ, Hirte HW, van der Biessen DAJ, Abdul Razak AR, De Vos FYFL, Verheijen RB, Schnell D, Pronk LC, Jansen M, Siu LL. Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies. Target Oncol. 2019 Feb;14(1):43-55. doi: 10.1007/s11523-018-00617-1.
citation: Verheijen RB, van der Biessen DAJ, Hotte SJ, Siu LL, Spreafico A, de Jonge MJA, Pronk LC, De Vos FYFL, Schnell D, Hirte HW, Steeghs N, Lolkema MP. Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520. Target Oncol. 2019 Feb;14(1):67-74. doi: 10.1007/s11523-018-00618-0.